Back to Search
MATTHEW HUEMAN, M.D.
M.D.
Surgical Oncology Physician
NPI: 1780621656IndividualAccepts Medicare
Specialties, Licenses & Credentials
Surgery Physician
Surgery
Code: 208600000X
01056708A(IN)0101232968(VA)
Surgical Oncology PhysicianPrimary
Surgery — Surgical Oncology
Code: 2086X0206X
MD047745(DC)D0066188(MD)0101232968(VA)
Education
DUKE UNIVERSITY SCHOOL OF MEDICINE
Class of 2000
Research & Publications (20)
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
PMID 19351776·Clin Cancer Res·2009
3-trial
Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.
PMID 19228530·J Am Coll Surg·2009
2-rct
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
PMID 18726994·Cancer·2008
3-trial
Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
PMID 18612158·J Clin Oncol·2008
3-trial
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
PMID 18392824·Cancer Immunol Immunother·2008
3-trial
Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
PMID 18245541·Clin Cancer Res·2008
3-trial
Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.
PMID 17906897·Ann Surg Oncol·2007
8-other
Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology.
PMID 17273752·Oncol Rep·2007
3-trial
Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine.
PMID 16783576·Cancer Immunol Immunother·2007
3-trial
Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.
PMID 16758122·Breast Cancer Res Treat·2006
8-other
Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients.
PMID 16428490·Clin Cancer Res·2006
8-other
Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
PMID 16243821·Clin Cancer Res·2005
3-trial
Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
PMID 16157940·J Clin Oncol·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 44035 RIVERSIDE PKWY STE 310
LEESBURG, VA 20176 - Phone
- (571) 350-8400
Quick Facts
- NPI
- 1780621656
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 5
- Locations
- 1
- Years in Practice
- 26
- Publications
- 20
Are you this provider?
Claim Your Profile